English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Symptomatic vasospasm (SVS) can occur after subarachnoid hemorrhage (SAH) and has been considered as a factor associated with negative prognosis in SAH. However, no standard method for preventing SVS is currently available. Various preventive methods have thus been developed and conducted in each institution. To obtain a standardized preventive method for SVS after SAH, the present multi-institutional cooperative clinical study of fasudil hydrochloride was conducted in 5 institutions in Kanagawa Prefecture. Subjects comprised 112 SAH patients Frequency of AVS at 1 week after onset of SAH was 56% in all subjects, with 81% for Oz, 55% for Fa and 41% for Ni. A significant difference was observed between Oz and the other treatment groups. Frequency of SVS for all subjects was 22%, with 23% for Fa, 13% for Ni and 35% for Oz. A significant difference was noted between Ni and Oz groups. In the evaluation of Glasgow outcome scale (GOS) after 3 months, good recovery (GR) was achieved by 64% of all subjects, with 70% for Fa, 68% for Ni and 48% for Oz. A significant difference was identified between Fa and Oz groups. Fasudil hydrochloride is recommended for use as a standard therapeutic drug in SAH treatment.

The Results of Multi-institutional Cooperative Clinical Study for Fasudil Hydrochloride in Kanagawa Prefecture